Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions

• Published in: Antimicrobial agents and chemotherapy Vol. 62; no. 12
• Main Authors: Ba, Boubakar, Gaudin, Karen, Désiré, Amélie, Phoeung, Thida, Langlois, Marie-Hélène, Behl, Charan R., Unowsky, Joel, Patel, Indravadan H., Malick, A. Waseem, Gomes, Melba, White, Nicholas, Kauss, Tina
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.12.2018
• Subjects: Administration, Rectal; Adult; Animals; Anti-Bacterial Agents; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - pharmacokinetics; Biological Availability; Ceftriaxone; Ceftriaxone - blood; Ceftriaxone - pharmacokinetics; Chenodeoxycholic Acid; Chenodeoxycholic Acid - administration & dosage; Clinical Therapeutics; Drug Administration Schedule; Drug Evaluation, Preclinical; Editor's Pick; Female; Healthy Volunteers; Humans; Infant, Newborn; Intestinal Absorption; Intestinal Absorption - drug effects; Male; Neonatal Sepsis - drug therapy; Neonatal Sepsis - prevention & control; Papio; Rabbits; Triglycerides; Triglycerides - administration & dosage; antibiotic; third-generation cephalosporins; pediatric drug therapy; pediatric; rectal route
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.01170-18

Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. This article presents all available data on the nonparenteral absorption of ceftriaxone in humans and animals, including unpublished work carried out by F. Hoffmann-La Roche (Roche) in the 1980s and new data from preclinical studies with rabbits, and discusses the importance of these data for the development of noninjectable formulations for noninvasive treatment. The combined results indicate that the rectal absorption of ceftriaxone is feasible and likely to lead to a bioavailable formulation that can reduce treatment delays in neonatal sepsis. A bile salt, chenodeoxycholate sodium salt (Na-CDC), used as an absorption enhancer at a 125-mg dose, together with a 500-mg dose of ceftriaxone provided 24% rectal absorption of ceftriaxone and a maximal plasma concentration of 21 µg/ml with good tolerance in human subjects. The rabbit model developed can also be used to screen for the bioavailability of other formulations before assessment in humans.